These include the large number of alleles examined, our use of clinically relevant hotspot missense Fbxw7 and Trp53 mutations, detailed tumour phenotyping including expert pathological review, agnostic approach to identify novel candidate FBXW7 substrates which were formally confirmed by co‐immunoprecipitation, and confirmation of LEF1 signature in human endometrial cancers with FBXW7 mutation. The gene discussed is LEF1; the disease is endometrial cancer.